{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:32:42Z","timestamp":1794641562642,"version":"4.9.1"},"reference-count":238,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["95886"],"award-info":[{"award-number":["95886"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.heliyon.2024.e40756","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T12:38:35Z","timestamp":1732797515000},"page":"e40756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Recent advances in potential enzymes and their therapeutic inhibitors for the treatment of Alzheimer's disease"],"prefix":"10.1016","volume":"10","author":[{"given":"Zahra Farajzadeh","family":"Vahid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Eskandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Dadashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3400-4109","authenticated-orcid":false,"given":"Somayeh","family":"Vandghanooni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e40756_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.129307","article-title":"Microwave-assisted synthesis, biological assessment, and molecular modeling of aza-heterocycles: potential inhibitory capacity of cholinergic enzymes to Alzheimer's disease","volume":"1224","author":"Polo","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.heliyon.2024.e40756_bib2","first-page":"14","article-title":"Boswellic acids as promising leads in drug development against Alzheimer's disease","volume":"27","author":"Haghaei","year":"2021","journal-title":"Pharmaceut. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/1759091421994351","article-title":"The potential roles of redox enzymes in Alzheimer's disease: focus on thioredoxin","volume":"13","author":"Jia","year":"2021","journal-title":"ASN neuro"},{"key":"10.1016\/j.heliyon.2024.e40756_bib4","series-title":"Alzheimer's Is a Multifactorial Disease","author":"Samanta","year":"2022"},{"key":"10.1016\/j.heliyon.2024.e40756_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4103\/1673-5374.245463","article-title":"Multitarget therapeutic strategies for Alzheimer's disease","volume":"14","author":"Ibrahim","year":"2019","journal-title":"Neural regeneration research"},{"key":"10.1016\/j.heliyon.2024.e40756_bib6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2174\/156720508783954785","article-title":"Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease","volume":"5","author":"Nalivaeva","year":"2008","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.heliyon.2024.e40756_bib7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41586-019-1195-2","article-title":"Single-cell transcriptomic analysis of Alzheimer's disease","volume":"570","author":"Mathys","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e40756_bib8","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s11064-019-02756-x","article-title":"Powering amyloid beta degrading enzymes: a possible therapy for Alzheimer's disease","volume":"44","author":"Sikanyika","year":"2019","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.heliyon.2024.e40756_bib9","article-title":"The beta-secretase BACE1 in Alzheimer's disease","volume":"13","author":"Hampel","year":"2020","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.heliyon.2024.e40756_bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/molecules26020388","article-title":"Probing mechanisms and therapeutic potential of \u03b3-secretase in Alzheimer's disease","volume":"26","author":"Wolfe","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.heliyon.2024.e40756_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1471-4159.2011.07510.x","article-title":"Are amyloid\u2010degrading enzymes viable therapeutic targets in Alzheimer's disease?","volume":"120","author":"Nalivaeva","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.algal.2024.103610","article-title":"Microalgae and cyanobacteria as natural sources of antioxidant enzymes and enzyme inhibitors for Alzheimer's and diabetes","volume":"82","author":"Odenthal","year":"2024","journal-title":"Algal Res."},{"key":"10.1016\/j.heliyon.2024.e40756_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1582-4934.2008.00314.x","article-title":"Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease","volume":"12","author":"Farfara","year":"2008","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.heliyon.2024.e40756_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2020.00220","article-title":"Decreased deposition of beta-amyloid 1-38 and increased deposition of beta-amyloid 1-42 in brain tissue of presenilin-1 E280A familial Alzheimer's disease patients","volume":"12","author":"Dinkel","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13122","article-title":"Hypothesis review: Alzheimer's overture guidelines","volume":"33","author":"Ferrer","year":"2023","journal-title":"Brain Pathol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12035-013-8445-3","article-title":"The senescence hypothesis of disease progression in Alzheimer disease: an integrated matrix of disease pathways for FAD and SAD","volume":"48","author":"Hunter","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib18","doi-asserted-by":"crossref","unstructured":"Deng, J. and X. Gao. Analysis of Genetic Mechanisms, Clinical Characteristics and Pathological Changes in Familial Alzheimer's Disease and Sporadic Alzheimer's Disease.EDP Sciences. DOI: 10.1051\/bioconf\/202411103001.","DOI":"10.1051\/bioconf\/202411103001"},{"key":"10.1016\/j.heliyon.2024.e40756_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0925-4439(00)00031-4","article-title":"Regulation of Alzheimer \u03b2-amyloid precursor trafficking and metabolism","volume":"1502","author":"Gandy","year":"2000","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease"},{"key":"10.1016\/j.heliyon.2024.e40756_bib20","first-page":"1","article-title":"Towards a unitary hypothesis of Alzheimer's disease pathogenesis","author":"Area-Gomez","year":"2024","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.heliyon.2024.e40756_bib21","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1093\/brain\/awad159","article-title":"The amyloid cascade hypothesis: an updated critical review","volume":"146","author":"Kepp","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.heliyon.2024.e40756_bib22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2024.e40756_bib23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/ijms25010072","article-title":"Switching on\/off amyloid plaque formation in transgenic animal models of Alzheimer's disease","volume":"25","author":"Kozin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411241","article-title":"Molecular mechanism of zinc-dependent oligomerization of Alzheimer's amyloid-\u03b2 with taiwan (D7H) mutation","volume":"24","author":"Kechko","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-020-00391-7","article-title":"Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease","volume":"15","author":"Guo","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.heliyon.2024.e40756_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jns.2014.07.015","article-title":"Assessment of CSF A\u03b242 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies","volume":"345","author":"Tang","year":"2014","journal-title":"Journal of the neurological sciences"},{"key":"10.1016\/j.heliyon.2024.e40756_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002270","article-title":"APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases","volume":"14","author":"Lanoisel\u00e9e","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.heliyon.2024.e40756_bib28","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1007\/s12035-017-0806-x","article-title":"Trafficking in Alzheimer's disease: modulation of APP transport and processing by the transmembrane proteins LRP1, SorLA, SorCS1c, sortilin, and calsyntenin","volume":"55","author":"Eggert","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000464422","article-title":"Molecular pathogenesis of Alzheimer's disease: an update","volume":"24","author":"Sanabria-Castro","year":"2017","journal-title":"Ann. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib30","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.4103\/0366-6999.235112","article-title":"Research progress in the pathogenesis of Alzheimer's disease","volume":"131","author":"Chen","year":"2018","journal-title":"Chinese medical journal"},{"key":"10.1016\/j.heliyon.2024.e40756_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176816","article-title":"Evolving significance of kinase inhibitors in the management of Alzheimer's disease","author":"Ansari","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neulet.2004.01.060","article-title":"Alterations in human tau transcripts correlate with those of neurofilament in sporadic tauopathies","volume":"359","author":"Umeda","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.heliyon.2024.e40756_bib33","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1126\/science.aah6205","article-title":"Site-specific phosphorylation of tau inhibits amyloid-\u03b2 toxicity in Alzheimer's mice","volume":"354","author":"Ittner","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2024.e40756_bib34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fncel.2018.00338","article-title":"Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability","volume":"12","author":"Alonso","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2016.03.005","article-title":"Acetylated tau obstructs KIBRA-mediated signaling in synaptic plasticity and promotes tauopathy-related memory loss","volume":"90","author":"Tracy","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.heliyon.2024.e40756_bib36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12017-019-08584-0","article-title":"O-GlcNAcylation as a therapeutic target for Alzheimer's disease","volume":"22","author":"Park","year":"2020","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.heliyon.2024.e40756_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-39218-x","article-title":"Novel model of secreted human tau protein reveals the impact of the abnormal N-glycosylation of tau on its aggregation propensity","volume":"9","author":"Losev","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e40756_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.5483\/BMBRep.2018.51.6.077","article-title":"Degradation or aggregation: the ramifications of post-translational modifications on tau","volume":"51","author":"Park","year":"2018","journal-title":"BMB reports"},{"key":"10.1016\/j.heliyon.2024.e40756_bib39","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.4103\/1673-5374.274329","article-title":"Toxic tau: structural origins of tau aggregation in Alzheimer's disease","volume":"15","author":"Al Mamun","year":"2020","journal-title":"Neural Regeneration Research"},{"key":"10.1016\/j.heliyon.2024.e40756_bib40","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1134\/S002689332104004X","article-title":"Beta amyloid, tau protein, and neuroinflammation: an attempt to integrate different hypotheses of Alzheimer's disease pathogenesis","volume":"55","author":"Garbuz","year":"2021","journal-title":"Molecular Biology"},{"key":"10.1016\/j.heliyon.2024.e40756_bib41","article-title":"Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease","volume":"3","author":"Wang","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e40756_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.00247","article-title":"PHF-core tau as the potential initiating event for tau pathology in Alzheimer's disease","volume":"14","author":"Luna-Viramontes","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113203","article-title":"Necroptosis in Alzheimer's disease: potential therapeutic target","volume":"152","author":"Richard","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e40756_bib44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fncel.2018.00193","article-title":"Emerging roles of astrocytes in neuro-vascular unit and the tripartite synapse with emphasis on reactive gliosis in the context of Alzheimer's disease","volume":"12","author":"Liu","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib45","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.4103\/1673-5374.308076","article-title":"The plasminogen activating system in the pathogenesis of Alzheimer's disease","volume":"16","author":"Yepes","year":"2021","journal-title":"Neural Regeneration Research"},{"key":"10.1016\/j.heliyon.2024.e40756_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.17993","article-title":"Neprilysin inhibitors and risk of Alzheimer's disease: a future perspective","volume":"28","author":"Ali","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.heliyon.2024.e40756_bib47","article-title":"Redox-active metal ions and amyloid-degrading enzymes in Alzheimer's disease","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemolab.2023.105049","article-title":"Machine learning-based q-RASAR approach for the in silico identification of novel multi-target inhibitors against Alzheimer's disease","volume":"245","author":"Kumar","year":"2024","journal-title":"Chemometr. Intell. Lab. Syst."},{"key":"10.1016\/j.heliyon.2024.e40756_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2021.06.029","article-title":"The transcriptional landscape of Alzheimer's disease and its association with Wnt signaling pathway","author":"Mart\u00ednez","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.heliyon.2024.e40756_bib50","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.18632\/aging.102830","article-title":"Riluzole: a therapeutic strategy in Alzheimer's disease by targeting the WNT\/\u03b2-catenin pathway","volume":"12","author":"Vall\u00e9e","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.heliyon.2024.e40756_bib51","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jsbmb.2014.06.010","article-title":"Estrogen receptor \u03b1 promotes non-amyloidogenic processing of platelet amyloid precursor protein via the MAPK\/ERK pathway","volume":"144","author":"Shi","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib52","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/s41593-019-0432-1","article-title":"Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis","volume":"22","author":"Esteve","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib53","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000334300","article-title":"Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein","volume":"10","author":"Holthoewer","year":"2012","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.heliyon.2024.e40756_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13033","article-title":"Facilitation of glutamate, but not GABA, release in Familial Alzheimer's APP mutant Knock\u2010in rats with increased \u03b2\u2010cleavage of APP","volume":"18","author":"Tambini","year":"2019","journal-title":"Aging Cell"},{"key":"10.1016\/j.heliyon.2024.e40756_bib55","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The \u03b2-secretase BACE1 in Alzheimer's disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.heliyon.2024.e40756_bib56","doi-asserted-by":"crossref","first-page":"41245","DOI":"10.1074\/jbc.M112.409110","article-title":"Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease","volume":"287","author":"Jeppsson","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2020.106536","article-title":"Computational modelling of potent \u03b2-secretase (BACE1) inhibitors towards Alzheimer's disease treatment","volume":"270","author":"Ugbaja","year":"2021","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2021.104622","article-title":"Neuregulin 1\/ErbB4\/Akt signaling attenuates cytotoxicity mediated by the APP-CT31 fragment of amyloid precursor protein","volume":"120","author":"Yoo","year":"2021","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib59","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1039\/D0MD00196A","article-title":"Recent developments of small molecule \u03b3-secretase modulators for Alzheimer's disease","volume":"11","author":"Mekala","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-020-00622-5","article-title":"\u03b3-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse \u03b3-secretase modulators do not","volume":"12","author":"Lessard","year":"2020","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.heliyon.2024.e40756_bib61","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202560","article-title":"Preclinical validation of a potent \u03b3-secretase modulator for Alzheimer's disease prevention","volume":"218","author":"Rynearson","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.heliyon.2024.e40756_bib62","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/jnr.23570","article-title":"Silent information regulator 1 modulator resveratrol increases brain lactate production and inhibits mitochondrial metabolism, whereas SRT1720 increases oxidative metabolism","volume":"93","author":"Rowlands","year":"2015","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.heliyon.2024.e40756_bib63","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.biopha.2017.10.075","article-title":"The role of SIRT1 in diabetic retinopathy","volume":"97","author":"Karbasforooshan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e40756_bib64","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1471-4159.2010.07081.x","article-title":"Alpha\u2010secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential","volume":"116","author":"Lichtenthaler","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8152373","article-title":"Neuroprotective mechanisms of resveratrol in Alzheimer's disease: role of SIRT1","volume":"2018","author":"Gomes","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.heliyon.2024.e40756_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.585821","article-title":"SIRT1 and SIRT2 activity control in neurodegenerative diseases","volume":"11","author":"Manjula","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.niox.2013.04.001","article-title":"Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol","volume":"32","author":"Xia","year":"2013","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.heliyon.2024.e40756_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101431","article-title":"BxPC-3-derived small extracellular vesicles induce FOXP3+ Treg through ATM-AMPK-Sirtuins-mediated FOXOs nuclear translocations","volume":"23","author":"Shen","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.heliyon.2024.e40756_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-35687-8","article-title":"A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer's disease mouse model","volume":"8","author":"Campagna","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e40756_bib70","doi-asserted-by":"crossref","first-page":"10426","DOI":"10.3390\/ijms160510426","article-title":"Humic acid increases amyloid \u03b2-induced cytotoxicity by induction of ER stress in human SK-N-MC neuronal cells","volume":"16","author":"Li","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib71","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.bbrc.2014.04.019","article-title":"Taurine attenuates amyloid \u03b2 1\u201342-induced mitochondrial dysfunction by activating of SIRT1 in SK-N-SH cells","volume":"447","author":"Sun","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2024.e40756_bib72","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.npep.2018.07.001","article-title":"Sirtuin 1 and Alzheimer's disease: an up-to-date review","volume":"71","author":"Rizzi","year":"2018","journal-title":"Neuropeptides"},{"key":"10.1016\/j.heliyon.2024.e40756_bib73","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13194","article-title":"RTN4B\u2010mediated suppression of Sirtuin 2 activity ameliorates \u03b2\u2010amyloid pathology and cognitive impairment in Alzheimer's disease mouse model","volume":"19","author":"Wang","year":"2020","journal-title":"Aging Cell"},{"key":"10.1016\/j.heliyon.2024.e40756_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.962769","article-title":"Sirtuins promote brain homeostasis, preventing Alzheimer's disease through targeting neuroinflammation","volume":"13","author":"Watroba","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib75","first-page":"518","article-title":"Sirtuin 2 (SIRT2): confusing roles in the pathophysiology of neurological disorders","volume":"15","author":"Chen","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172847","article-title":"Review of the anti-inflammatory effect of SIRT1 and SIRT2 modulators on neurodegenerative diseases","volume":"867","author":"Zhang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib77","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/15376516.2020.1729915","article-title":"AK-1, a Sirt2 inhibitor, alleviates carbon tetrachloride-induced hepatotoxicity in vivo and in vitro","volume":"30","author":"Zhou","year":"2020","journal-title":"Toxicol. Mech. Methods"},{"key":"10.1016\/j.heliyon.2024.e40756_bib78","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.1007\/s12035-018-0977-0","article-title":"Amyloid-\u03b2 increases tau by mediating sirtuin 3 in Alzheimer's disease","volume":"55","author":"Yin","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104851","article-title":"Antioxidant modulation of sirtuin 3 during acute inflammatory pain: the ROS control","volume":"157","author":"Ilari","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.heliyon.2024.e40756_bib80","article-title":"Sirtuin 3 mRNA expression is downregulated in the brain tissues of Alzheimer's disease patients: a bioinformatic and data mining approach","volume":"26","author":"Song","year":"2020","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res.: International Medical Journal of Experimental and Clinical Research"},{"key":"10.1016\/j.heliyon.2024.e40756_bib81","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.neuro.2020.04.006","article-title":"Targeting sirtuin activity with nicotinamide riboside reduces neuroinflammation in a GWI mouse model","volume":"79","author":"Joshi","year":"2020","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.heliyon.2024.e40756_bib82","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3233\/JAD-190014","article-title":"Sirtuin 3 mediates tau deacetylation","volume":"69","author":"Li","year":"2019","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.heliyon.2024.e40756_bib83","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s11064-016-2110-y","article-title":"Sirtuins and their roles in brain aging and neurodegenerative disorders","volume":"42","author":"J\u0119\u015bko","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.heliyon.2024.e40756_bib84","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.nbd.2010.09.016","article-title":"Brain molecular aging, promotion of neurological disease and modulation by sirtuin 5 longevity gene polymorphism","volume":"41","author":"Glorioso","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.heliyon.2024.e40756_bib85","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1021\/acs.jmedchem.7b01648","article-title":"Potent and selective inhibitors of human sirtuin 5","volume":"61","author":"Kalbas","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib86","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cmet.2014.03.014","article-title":"Lysine glutarylation is a protein posttranslational modification regulated by SIRT5","volume":"19","author":"Tan","year":"2014","journal-title":"Cell Metabol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib87","series-title":"Irtuin 6 Is Reduced in Alzheimer's Disease (5101)","article-title":"S","author":"Shi","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e40756_bib88","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10517-020-04986-4","article-title":"Sirtuins as possible predictors of aging and Alzheimer's disease development: verification in the hippocampus and saliva","volume":"169","author":"Pukhalskaia","year":"2020","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.heliyon.2024.e40756_bib89","series-title":"Post-Translational Modifications of the P53 Protein and the Impact in Alzheimer's Disease: A Review of the Literature","author":"Clark","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e40756_bib90","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.3390\/ijms22084180","article-title":"A comprehensive analysis into the therapeutic application of natural products as SIRT6 modulators in Alzheimer's disease, aging, cancer, inflammation, and diabetes","volume":"22","author":"Akter","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib91","series-title":"Autophagic Plasmid Expressing SIRT3 and SIRT4 to Improve Alzheimer's Disease","author":"Li","year":"2022"},{"key":"10.1016\/j.heliyon.2024.e40756_bib92","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1021\/acschemneuro.1c00468","article-title":"SIRT5 represses neurotrophic pathways and a\u03b2 production in Alzheimer's disease by targeting autophagy","volume":"12","author":"Wu","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib93","article-title":"Overview of SIRT5 as a potential therapeutic target: structure, function and inhibitors","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169027","article-title":"SIRT7 deficiency Protects against a\u03b242-induced Apoptosis through the Regulation of NOX4-derived reactive oxygen species Production in SH-SY5Y cells","volume":"23","author":"Mizutani","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib95","unstructured":"Sub Laban T, Saadabadi A. Monoamine Oxidase Inhibitors (MAOI) [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539848\/."},{"key":"10.1016\/j.heliyon.2024.e40756_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112787","article-title":"A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer\u2019s disease agents: a review","author":"Manzoor","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib97","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.2174\/138161210793176572","article-title":"Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease","volume":"16","author":"Agostinho","year":"2010","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.heliyon.2024.e40756_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26123724","article-title":"Role of monoamine oxidase activity in Alzheimer's disease: an insight into the therapeutic potential of inhibitors","volume":"26","author":"Behl","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.heliyon.2024.e40756_bib99","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00702-018-1861-9","article-title":"Kinetics, mechanism, and inhibition of monoamine oxidase","volume":"125","author":"Ramsay","year":"2018","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.heliyon.2024.e40756_bib100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.brainres.2009.04.010","article-title":"Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type","volume":"1281","author":"Ishrat","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.heliyon.2024.e40756_bib101","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/17425255.2017.1273901","article-title":"Use of monoamine oxidase inhibitors in chronic neurodegeneration","volume":"13","author":"Riederer","year":"2017","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib102","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8954201","article-title":"Monoamine oxidase-related vascular oxidative stress in diseases associated with inflammatory burden","volume":"2019","author":"Sturza","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.heliyon.2024.e40756_bib103","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/13543776.2014.982535","article-title":"Novel monoamine oxidase inhibitors: a patent review (2012\u20132014)","volume":"25","author":"Carradori","year":"2015","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.heliyon.2024.e40756_bib104","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejmech.2019.05.039","article-title":"Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase","volume":"177","author":"Kumar","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib105","series-title":"4th INTERNATIONAL CONFERENCE on ADVANCES IN NATURAL & APPLIED SCIENCES","article-title":"Determination of inhibition effect of Plantago Major plant extract on monoamine oxidase isoenzymes (MAO-A and MAO-B). IC","author":"Akincio\u011eLu","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e40756_bib106","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.freeradbiomed.2021.05.019","article-title":"Myricetin prevents high molecular weight A\u03b21-42 oligomer-induced neurotoxicity through antioxidant effects in cell membranes and mitochondria","volume":"171","author":"Kimura","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.heliyon.2024.e40756_bib107","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13543776.2018.1427735","article-title":"MAO inhibitors and their wider applications: a patent review","volume":"28","author":"Carradori","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.heliyon.2024.e40756_bib108","article-title":"Bilobalide alleviates neuroinflammation and promotes autophagy in Alzheimer's disease by upregulating lincRNA-p21","volume":"13","author":"Qin","year":"2021","journal-title":"American Journal of Translational Research"},{"key":"10.1016\/j.heliyon.2024.e40756_bib109","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00702-018-1942-9","article-title":"Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases","volume":"125","author":"Youdim","year":"2018","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.heliyon.2024.e40756_bib110","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1134\/S0006297909010155","article-title":"Catalytic activity and stability of xanthine oxidase in aqueous-organic mixtures","volume":"74","author":"Rashidi","year":"2009","journal-title":"Biochemistry (Moscow)"},{"key":"10.1016\/j.heliyon.2024.e40756_bib111","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/clpt.1991.205","article-title":"Human liver xanthine oxidase: nature and extent of individual variation","volume":"50","author":"Guerciolini","year":"1991","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.heliyon.2024.e40756_bib112","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2133\/dmpk.22.299","article-title":"In vitro study of 6-mercaptopurine oxidation catalysed by aldehyde oxidase and xanthine oxidase","volume":"22","author":"Rashidi","year":"2007","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.heliyon.2024.e40756_bib113","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1039\/D0QI01029D","article-title":"The complete catalytic mechanism of xanthine oxidase: a computational study","volume":"8","author":"Ribeiro","year":"2021","journal-title":"Inorg. Chem. Front."},{"key":"10.1016\/j.heliyon.2024.e40756_bib114","series-title":"Biochemistry, Xanthine Oxidase","author":"Aziz","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e40756_bib115","series-title":"Biochemistry, Xanthine Oxidase","author":"Aziz","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e40756_bib116","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF02261005","article-title":"The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease","volume":"6","author":"Tohgi","year":"1993","journal-title":"Journal of Neural Transmission - Parkinson's Disease and Dementia Section"},{"key":"10.1016\/j.heliyon.2024.e40756_bib117","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1755-5922.2011.00277.x","article-title":"Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta\u2010analysis","volume":"30","author":"Higgins","year":"2012","journal-title":"Cardiovascular therapeutics"},{"key":"10.1016\/j.heliyon.2024.e40756_bib118","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/00003088-200645080-00005","article-title":"Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects","volume":"45","author":"Khosravan","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.heliyon.2024.e40756_bib119","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/cmdc.201900034","article-title":"Inhibitors of xanthine oxidase: scaffold diversity and structure-based drug design","volume":"14","author":"Luna","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.heliyon.2024.e40756_bib120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10157-019-01804-8","article-title":"Febuxostat, a novel inhibitor of xanthine oxidase, reduces ER stress through upregulation of SIRT1-AMPK-HO-1\/thioredoxin expression","volume":"24","author":"Kim","year":"2020","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib121","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11255-017-1733-5","article-title":"Allopurinol protects human glomerular endothelial cells from high glucose-induced reactive oxygen species generation, p53 overexpression and endothelial dysfunction","volume":"50","author":"Eleftheriadis","year":"2018","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib122","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3892\/br.2016.630","article-title":"Role of oxidative stress in Alzheimer's disease","volume":"4","author":"Huang","year":"2016","journal-title":"Biomedical reports"},{"key":"10.1016\/j.heliyon.2024.e40756_bib123","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12011-011-9291-7","article-title":"Aldehyde and xanthine oxidase activities in tissues of streptozotocin- induced diabetic rats: Effects of vitamin e and selenium supplementation","volume":"147","author":"Ghaffari","year":"2012","journal-title":"Biol. Trace Elem. Res."},{"key":"10.1016\/j.heliyon.2024.e40756_bib124","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3923\/pjbs.2008.1779.1784","article-title":"Effects of onion on serum uric acid levels and hepatic xanthinedehydrogenase\/xanthine oxidase activities in hyperuricemic rats","volume":"11","author":"Haidari","year":"2008","journal-title":"Pakistan J. Biol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib125","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2174\/1570180814666170420110005","article-title":"Inhibitory effects of flavonolignans from silybum marianum (L.) gaertn (milk thistle) on function of aldehyde oxidase and xanthine oxidase in rats","volume":"15","author":"Alizadeh","year":"2018","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.heliyon.2024.e40756_bib126","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/cbdd.13437","article-title":"Natural compounds with xanthine oxidase inhibitory activity: a review","volume":"93","author":"Mehmood","year":"2019","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.heliyon.2024.e40756_bib127","first-page":"1479","article-title":"Cholinesterase inhibitors as Alzheimer's therapeutics","volume":"20","author":"Sharma","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.heliyon.2024.e40756_bib128","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.3389\/fphar.2020.606656","article-title":"Fine tuning muscarinic acetylcholine receptor signaling through allostery and bias","volume":"11","author":"Van Der Westhuizen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib129","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.2174\/1381612825666191008103141","article-title":"Cholinesterase inhibitors for Alzheimer's disease: multitargeting strategy based on anti-Alzheimer's drugs repositioning","volume":"25","author":"Kabir","year":"2019","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.heliyon.2024.e40756_bib130","series-title":"Genetics, Neurology, Behavior, and Diet in Dementia","first-page":"457","article-title":"A\u03b242-\u03b17-like nicotinic acetylcholine receptors and Alzheimer's disease","author":"Wang","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e40756_bib131","series-title":"PET and SPECT in Neurology","first-page":"345","article-title":"PET imaging of the \u03b14\u03b22\u2217 nicotinic acetylcholine receptors in Alzheimer's disease","author":"Sabri","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e40756_bib132","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.coph.2020.09.016","article-title":"Lynx1 prototoxins: critical accessory proteins of neuronal nicotinic acetylcholine receptors","volume":"56","author":"Miwa","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib133","series-title":"Donepezil. StatPearls [Internet]","author":"Kumar","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e40756_bib134","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1517\/13543784.16.12.1987","article-title":"An update on the pharmacology of galantamine","volume":"16","author":"Villarroya","year":"2007","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.heliyon.2024.e40756_bib135","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13181-014-0452-x","article-title":"The use of physostigmine by toxicologists in anticholinergic toxicity","volume":"11","author":"Watkins","year":"2015","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib136","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7252882","article-title":"Tacrine derivatives in neurological disorders: focus on molecular mechanisms and neurotherapeutic potential","volume":"2022","author":"Mitra","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.heliyon.2024.e40756_bib137","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ejmech.2019.02.005","article-title":"Tacrines for Alzheimer's disease therapy. III. The PyridoTacrines","volume":"166","author":"de Los R\u00edos","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib138","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/(SICI)1097-0282(199601)38:1<109::AID-BIP9>3.0.CO;2-#","article-title":"Binding of tacrine and 6\u2010chlorotacrine by acetylcholinesterase","volume":"38","author":"Wlodek","year":"1996","journal-title":"Biopolymers: Original Research on Biomolecules"},{"key":"10.1016\/j.heliyon.2024.e40756_bib139","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/14756366.2019.1689237","article-title":"Novel tacrine\u2013benzofuran hybrids as potential multi-target drug candidates for the treatment of Alzheimer's Disease","volume":"35","author":"Fancellu","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117419","article-title":"Quinolinetrione-tacrine hybrids as multi-target-directed ligandsagainst Alzheimer's disease","volume":"91","author":"Uliassi","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib141","doi-asserted-by":"crossref","first-page":"27","DOI":"10.31782\/IJCRR.2021.131107","article-title":"Highlights on synthetic, natural, and hybrid cholinesterase inhibitors for effective treatment of Alzheimer's disease: a review","volume":"13","author":"Danao","year":"2021","journal-title":"Int J Cur Res Rev|"},{"key":"10.1016\/j.heliyon.2024.e40756_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104528","article-title":"(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice","volume":"130","author":"Lecca","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.heliyon.2024.e40756_bib143","article-title":"The use of Huperzia species for the treatment of Alzheimer's disease","volume":"31","author":"Thu","year":"2020","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib144","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jcma.2018.07.004","article-title":"Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease","volume":"82","author":"Gul","year":"2019","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.heliyon.2024.e40756_bib145","first-page":"1767","article-title":"Galangin decreases p-tau, A\u03b242 and \u03b2-secretase levels, and suppresses autophagy in okadaic acid-induced PC12 cells via an Akt\/GSK3\u03b2\/mTOR signaling-dependent mechanism","volume":"19","author":"Huang","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.heliyon.2024.e40756_bib146","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/brainsci11020184","article-title":"Anti-cholinesterase combination drug therapy as a potential treatment for Alzheimer's disease","volume":"11","author":"Amat-ur-Rasool","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib147","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/14756366.2018.1430691","article-title":"Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimer's disease","volume":"33","author":"Zhu","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib148","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1039\/C7MD00569E","article-title":"Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease","volume":"9","author":"Denya","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1016\/j.heliyon.2024.e40756_bib149","first-page":"1","article-title":"Computational design of new tacrine analogs: an in silico prediction of their cholinesterase inhibitory, antioxidant, and hepatotoxic activities","author":"Djafarou","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.heliyon.2024.e40756_bib150","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.3390\/ijms22063136","article-title":"The PKR\/P38\/RIPK1 signaling pathway as a therapeutic target in Alzheimer's disease","volume":"22","author":"Hugon","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib151","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biopsych.2017.06.004","article-title":"Targeting Fyn kinase in Alzheimer's disease","volume":"83","author":"Nygaard","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.heliyon.2024.e40756_bib152","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fnagi.2021.647990","article-title":"Cholesterol, atherosclerosis, and APOE in vascular contributionsto cognitive impairment and dementia (VCID): potential mechanisms and therapy","volume":"13","author":"Duong","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib153","article-title":"Sterol O-acyltransferase (SOAT\/ACAT) activity is required to form cholesterol crystals in hepatocyte lipid droplets","volume":"1869","author":"Bairos","year":"2024","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids"},{"key":"10.1016\/j.heliyon.2024.e40756_bib154","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fnagi.2020.00255","article-title":"Nicotinamide, a poly [ADP-ribose] polymerase 1 (PARP-1) inhibitor, as an adjunctive therapy for the treatment of Alzheimer's disease","volume":"12","author":"Salech","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103418","article-title":"Neurological and psychiatric management using COMT inhibitors: a review","volume":"94","author":"Akhtar","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib156","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.3390\/ijms22116047","article-title":"Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases (CLKs) in human disease, an overview","volume":"22","author":"Lindberg","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib157","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2174\/0929866527666191230103739","article-title":"Renin-angiotensin system and Alzheimer's disease pathophysiology: from the potential interactions to therapeutic perspectives","volume":"27","author":"Ribeiro","year":"2020","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.heliyon.2024.e40756_bib158","first-page":"288","article-title":"12\/15 Lipoxygenase as a therapeutic target in brain disorders","volume":"56","author":"Karatas","year":"2019","journal-title":"Archives of Neuropsychiatry"},{"key":"10.1016\/j.heliyon.2024.e40756_bib159","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11011-018-0322-3","article-title":"Alkaline phosphatase: a potential biomarker for stroke and implications for treatment","volume":"34","author":"Brichacek","year":"2019","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.heliyon.2024.e40756_bib160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-020-00195-1","article-title":"Peripheral clearance of brain-derived A\u03b2 in Alzheimer's disease: pathophysiology and therapeutic perspectives","volume":"9","author":"Cheng","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.heliyon.2024.e40756_bib161","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bph.14593","article-title":"Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy","volume":"176","author":"Nalivaeva","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib162","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12640-020-00185-1","article-title":"Exploring the promise of targeting ubiquitin-proteasome system to combat Alzheimer's disease","volume":"38","author":"Al Mamun","year":"2020","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.heliyon.2024.e40756_bib163","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fncel.2021.661612","article-title":"Pharmacological modulators of small GTPases of rho family in neurodegenerative diseases","volume":"15","author":"Guiler","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-017-0308-0","article-title":"PKR involvement in Alzheimer's disease","volume":"9","author":"Hugon","year":"2017","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.heliyon.2024.e40756_bib165","article-title":"Effect of Catechol-O-methyltransferase genotype polymorphism on neurological and psychiatric disorders: progressing towards personalized medicine","volume":"13","author":"Srivastava","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.heliyon.2024.e40756_bib166","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/sj.mp.4001709","article-title":"Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease","volume":"10","author":"Sweet","year":"2005","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.heliyon.2024.e40756_bib167","first-page":"1","article-title":"Fyn kinase in Alzheimer's disease: unraveling molecular mechanisms and therapeutic implications","author":"Meur","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt257","article-title":"The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease","volume":"6","author":"Jochemsen","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.heliyon.2024.e40756_bib169","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s40478-023-01647-1","article-title":"Higher angiotensin-converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease","volume":"11","author":"Reveret","year":"2023","journal-title":"Acta neuropathologica communications"},{"key":"10.1016\/j.heliyon.2024.e40756_bib170","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2174\/1570159X18666200924122732","article-title":"Inflammation drives Alzheimer's disease: emphasis on 5-lipoxygenase pathways","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176694","article-title":"Eicosanoid signaling in neuroinflammation associated with Alzheimer's disease","author":"Lohitaksha","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib172","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11064-015-1776-x","article-title":"The lipoxygenases: their regulation and implication in Alzheimer's disease","volume":"41","author":"Czapski","year":"2016","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.heliyon.2024.e40756_bib173","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.bbi.2020.03.022","article-title":"5-lipoxygenase pathway and its downstream cysteinyl leukotrienes aspotential therapeutic targets for Alzheimer's disease","volume":"88","author":"Chen","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.heliyon.2024.e40756_bib174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2047-9158-1-16","article-title":"Curcumin inhibition of JNKs prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease through suppressing mitochondria dysfunction","volume":"1","author":"Pan","year":"2012","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.heliyon.2024.e40756_bib175","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.chembiol.2011.11.010","article-title":"Discovery of potent and selective covalent inhibitors of JNK","volume":"19","author":"Zhang","year":"2012","journal-title":"Chemistry & biology"},{"key":"10.1016\/j.heliyon.2024.e40756_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114894","article-title":"Discovery of novel imidazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Alzheimer's disease","volume":"245","author":"Jun","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib177","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1055\/s-0044-100186","article-title":"GSK-3 inhibitors: a double-edged sword?\u2013An update on tideglusib","volume":"68","author":"Mathuram","year":"2018","journal-title":"Drug research"},{"key":"10.1016\/j.heliyon.2024.e40756_bib178","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/1061186X.2018.1474361","article-title":"Drug development for Alzheimer's disease","volume":"27","author":"Lao","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.heliyon.2024.e40756_bib179","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/ndt\/gfy291","article-title":"AL amyloidosis: advances in diagnostics and treatment","volume":"34","author":"Ry\u0161av\u00e1","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.heliyon.2024.e40756_bib180","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.2174\/1381612826666200518112355","article-title":"Cross-interplay between osmolytes and mTOR in Alzheimer's disease pathogenesis","volume":"26","author":"Mueed","year":"2020","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.heliyon.2024.e40756_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106549","article-title":"Current druggable targets for therapeutic control of Alzheimer's disease","volume":"109","author":"Gupta","year":"2021","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.heliyon.2024.e40756_bib182","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1080\/00207454.2019.1645142","article-title":"Cdk5: a main culprit in neurodegeneration","volume":"129","author":"Gupta","year":"2019","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib183","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jalz.2019.09.075","article-title":"The path forward in Alzheimer's disease therapeutics: reevaluating the amyloid cascade hypothesis","volume":"16","author":"Tolar","year":"2020","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.heliyon.2024.e40756_bib184","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1007\/s12035-020-02084-0","article-title":"The crosstalk between pathological tau phosphorylation and mitochondrial dysfunction as a key to understanding and treating Alzheimer's disease","volume":"57","author":"Guha","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib185","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2174\/1568026620666200106125910","article-title":"Targeting Tau hyperphosphorylation via kinase inhibition: strategy to address Alzheimer's disease","volume":"20","author":"Naqvi","year":"2020","journal-title":"Current topics in medicinal chemistry"},{"key":"10.1016\/j.heliyon.2024.e40756_bib186","article-title":"Src family kinases (SFKs): critical regulators of microglial homeostatic functions and neurodegeneration in Parkinson's and Alzheimer's diseases","author":"Portugal","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.heliyon.2024.e40756_bib187","doi-asserted-by":"crossref","DOI":"10.1177\/11795735211029113","article-title":"The state of the art on acetylcholinesterase inhibitors in the treatment of Alzheimer's disease","volume":"13","author":"Vecchio","year":"2021","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.heliyon.2024.e40756_bib188","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/nmt-2021-0019","article-title":"Masitinib for the treatment of Alzheimer's disease","volume":"11","author":"Ettcheto","year":"2021","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.heliyon.2024.e40756_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroscience.2021.06.013","article-title":"Potential repositioning of anti-cancer EGFR inhibitors in Alzheimer's disease: current perspectives and challenging prospects","author":"Mansour","year":"2021","journal-title":"Neuroscience"},{"key":"10.1016\/j.heliyon.2024.e40756_bib190","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5483\/BMBRep.2019.52.1.290","article-title":"Sirtuin signaling in cellular senescence and aging","volume":"52","author":"Lee","year":"2019","journal-title":"BMB reports"},{"key":"10.1016\/j.heliyon.2024.e40756_bib191","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.3390\/ijms21113858","article-title":"Relevance of SIRT1-NF-\u03baB axis as therapeutic target to ameliorate inflammation in liver disease","volume":"21","author":"de Gregorio","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib192","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.3389\/fphar.2020.585821","article-title":"SIRT1 and SIRT2 activity control in neurodegenerative diseases","volume":"11","author":"Manjula","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib193","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejmech.2018.01.003","article-title":"Privileged scaffolds as MAO inhibitors: retrospect and prospects","volume":"145","author":"Tripathi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib194","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.2174\/1381612826666200406075044","article-title":"Exploring the multifunctional neuroprotective promise of rasagiline derivatives for multi-dysfunctional Alzheimer's disease","volume":"26","author":"Uddin","year":"2020","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.heliyon.2024.e40756_bib195","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/npp.2014.214","article-title":"Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain","volume":"40","author":"Fowler","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.heliyon.2024.e40756_bib196","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099271","article-title":"Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity","volume":"9","author":"Odaka","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e40756_bib197","first-page":"1","article-title":"Importance of ethnopharmacological studies in drug discovery: role of medicinal plants","author":"S\u00fcntar","year":"2019","journal-title":"Phytochemistry Rev."},{"key":"10.1016\/j.heliyon.2024.e40756_bib198","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12035-020-02116-9","article-title":"Multi-target drug candidates for multifactorial Alzheimer's disease: AChE and NMDAR as molecular targets","volume":"58","author":"Uddin","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib199","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.tips.2020.04.008","article-title":"A perspective on multi-target drugs for Alzheimer's disease","volume":"41","author":"Benek","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24098312","article-title":"Rivastigmine-benzimidazole hybrids as promising multitarget metal-modulating compounds for potential treatment of neurodegenerative diseases","volume":"24","author":"Vicente-Zurdo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib201","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.2174\/1389450119666180406110743","article-title":"New light on an old friend: targeting PUMA in radioprotection and therapy of cardiovascular and neurodegenerative diseases","volume":"19","author":"Tichy","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.heliyon.2024.e40756_bib202","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2147\/DDDT.S300988","article-title":"Role of p38 mitogen-activated protein kinase in asthma and COPD: pathogenic aspects and potential targeted therapies","volume":"15","author":"Pelaia","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.heliyon.2024.e40756_bib203","doi-asserted-by":"crossref","DOI":"10.2174\/1568011817666200928114851","article-title":"Allosteric inhibitors of SHP2: an updated patent review (2015-2020)","author":"Wu","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib204","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2174\/0929867327666200210144114","article-title":"Recent advances in c-Jun N-terminal kinase (JNK) Inhibitors","volume":"28","author":"Li","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib205","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.3390\/ijms21124444","article-title":"Fyn tyrosine kinase as harmonizing factor in neuronal functions and dysfunctions","volume":"21","author":"Matrone","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib206","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1039\/D0MD00227E","article-title":"Recent developments in anticancer kinase inhibitors based on the pyrazolo [3, 4-d] pyrimidine scaffold","volume":"11","author":"Baillache","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib207","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2174\/0929867327666200713185413","article-title":"Recent advances in the development of casein kinase 1 inhibitors","volume":"28","author":"Li","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111581","article-title":"Small molecule modulators targeting protein kinase CK1 and CK2","volume":"181","author":"Qiao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib209","article-title":"Recent research and development of DYRK1A inhibitors","author":"Zhao","year":"2021","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.heliyon.2024.e40756_bib210","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ejmech.2018.08.093","article-title":"DYRK1A kinase inhibition with emphasis on neurodegeneration: a comprehensive evolution story-cum-perspective","volume":"158","author":"Pathak","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib211","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3389\/fphys.2020.574030","article-title":"Protein kinase inhibitor peptide as a tool to specifically inhibit protein kinase A","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib212","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3389\/fphar.2021.648636","article-title":"PI3K\/AKT signal pathway: a target of natural products in the prevention and treatment of Alzheimer's disease and Parkinson's disease","volume":"12","author":"Long","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib213","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2174\/1389450122666210120143953","article-title":"Recent advances in the discovery of GSK-3 inhibitors from synthetic origin in the treatment of neurological disorders","volume":"22","author":"Saha","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.heliyon.2024.e40756_bib214","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fendo.2018.00133","article-title":"Tau phosphorylation in female neurodegeneration: role of estrogens, progesterone, and prolactin","volume":"9","author":"Mu\u00f1oz-Mayorga","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib215","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coph.2021.11.008","article-title":"Targeting PKC in microglia to promote remyelination and repair in the CNS","volume":"62","author":"Kim","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e40756_bib216","doi-asserted-by":"crossref","DOI":"10.2174\/0929867328666210329124415","article-title":"Natural sirtuin modulators in drug discovery: a review (2010-2020)","author":"Chang","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib217","doi-asserted-by":"crossref","first-page":"37382","DOI":"10.1039\/D0RA06316A","article-title":"Recent advances in the development of histone deacylase SIRT2 inhibitors","volume":"10","author":"Yang","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.heliyon.2024.e40756_bib218","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4155\/fmc-2017-0207","article-title":"Recent advances in inhibitors of sirtuin1\/2: an update and perspective","volume":"10","author":"Zhou","year":"2018","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib219","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2174\/1389557516666160620095103","article-title":"Small molecules as SIRT modulators","volume":"18","author":"Bai","year":"2018","journal-title":"Mini reviews in medicinal chemistry"},{"key":"10.1016\/j.heliyon.2024.e40756_bib220","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.2174\/092986711803414359","article-title":"An update on natural occurrence and biological activity of chromones","volume":"18","author":"K Sharma","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib221","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113709","article-title":"Selective SIRT2 inhibitors as promising anticancer therapeutics: an update from 2016 to 2020","volume":"224","author":"Roshdy","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib222","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pharmthera.2018.03.004","article-title":"Sirtuin activators and inhibitors: promises, achievements, and challenges","volume":"188","author":"Dai","year":"2018","journal-title":"Pharmacology & therapeutics"},{"key":"10.1016\/j.heliyon.2024.e40756_bib223","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4155\/fmc.14.44","article-title":"Sirtuin inhibitors as anticancer agents","volume":"6","author":"Hu","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib224","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbamcr.2013.03.004","article-title":"The sirtuin inhibitor cambinol impairs MAPK signaling, inhibits inflammatory and innate immune responses and protects from septic shock","volume":"1833","author":"Lugrin","year":"2013","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Cell Research"},{"key":"10.1016\/j.heliyon.2024.e40756_bib225","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2174\/138161213804581954","article-title":"Rejuvenating sirtuins: the rise of a new family of cancer drug targets","volume":"19","author":"Bruzzone","year":"2013","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.heliyon.2024.e40756_bib226","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2174\/18715273113126660166","article-title":"Current acetylcholinesterase-Inhibitors: a neuroinformatics perspective. CNS & neurological disorders-drug targets","volume":"13","author":"Shaikh","year":"2014","journal-title":"Formerly Current Drug Targets-CNS & Neurological Disorders)"},{"key":"10.1016\/j.heliyon.2024.e40756_bib227","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/13543776.2017.1272571","article-title":"Recent advances in acetylcholinesterase inhibitors and reactivators: an update on the patent literature (2012-2015)","volume":"27","author":"McHardy","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.heliyon.2024.e40756_bib228","first-page":"456","article-title":"Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease","volume":"13","author":"C Motel","year":"2013","journal-title":"Mini reviews in medicinal chemistry"},{"key":"10.1016\/j.heliyon.2024.e40756_bib229","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1021\/acschemneuro.1c00184","article-title":"Phenothiazine-tacrine heterodimers: pursuing multitarget DirectedApproach in Alzheimer's disease","volume":"12","author":"Gorecki","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021717","article-title":"Tacrine-based hybrids: past, present, and future","volume":"24","author":"Bubley","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e40756_bib231","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11696-018-0590-8","article-title":"Tacrine hybrids as multi-target-directed ligands in Alzheimer's disease: influence of chemical structures on biological activities","volume":"73","author":"Girek","year":"2019","journal-title":"Chem. Pap."},{"key":"10.1016\/j.heliyon.2024.e40756_bib232","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.2174\/092986707782023217","article-title":"Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment","volume":"14","author":"Musial","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib233","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.15379","article-title":"Promising tacrine\/huperzine A\u2010based dimeric AChE inhibitors for neurodegenerative disorders: from relieving symptoms to modifying diseases through multi\u2010target","author":"Mak","year":"2021","journal-title":"J. Neurochem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib234","doi-asserted-by":"crossref","DOI":"10.4155\/fmc-2021-0119","article-title":"Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion?","author":"Matos","year":"2021","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e40756_bib235","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101062","article-title":"The multi-faceted impact of methamphetamine on Alzheimer's disease: from a triggering role to a possible therapeutic use","volume":"60","author":"Shukla","year":"2020","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.heliyon.2024.e40756_bib236","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/164_2020_384","article-title":"Monoamine oxidase inhibitors: from classic to new clinical approaches","author":"Duarte","year":"2020","journal-title":"Reactive Oxygen Species"},{"key":"10.1016\/j.heliyon.2024.e40756_bib237","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2174\/1386207323666200220115154","article-title":"Vital role of monoamine oxidases and cholinesterases in central nervous system drug research: a sharp dissection of the pathophysiology","volume":"23","author":"Aksoz","year":"2020","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"10.1016\/j.heliyon.2024.e40756_bib238","first-page":"1","article-title":"Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence","author":"Ulrich","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.heliyon.2024.e40756_bib239","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911059","article-title":"Neuroprotective function of rasagiline and selegiline, inhibitors of type B monoamine oxidase, and role of monoamine oxidases in synucleinopathies","volume":"23","author":"Naoi","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024167874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024167874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:38:47Z","timestamp":1790545127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024167874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":238,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2405844024167874"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e40756","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in potential enzymes and their therapeutic inhibitors for the treatment of Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e40756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e40756"}}